Clinical trial
Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial.
NCT02248428 is registered in ClinicalTrials.gov with Jinling Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial.
- Lead sponsor
- Jinling Hospital, China
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- April 30, 2012
- Completion date
- September 30, 2020
- Enrollment
- 130 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.